Avcade (infliximab biosimilar) / Avesthagen - LARVOL DELTA

Biosimilars Match Biologic Originators in Rheumatoid Arthritis (RheumNow) - "A systematic review and meta-analysis in JAMA Network Open has shown that biosimilars of adalimumab, infliximab, and etanercept were associated with clinically equivalent treatment effects compared with their reference biologics for the treatment of rheumatoid arthritis (RA)....This review finds that biosimilars may yield therapeutically equivalent outcomes compared with reference biologic drugs for the management of rheumatoid arthritis."

Online posting

More than 60% of Crohn’s patients sustained remission with subcutaneous biosimilar CT-P13 (Healio) - "'In the past several years, there have been a number of formulations of infliximab that have met criteria for what is known as biosimilarity,' Stephen B. Hanauer...The overall outcome is actually improved by subcutaneous administration compared to intravenous infusions and maintenance treatment.'"

Media quote

Fewer Discontinuations With Infliximab vs Vedolizumab for UC Maintenance Therapy (Medscape) - "'We know that vedolizumab has less safety risks than an anti-TNF agent, but we also have the gut feeling that the anti-TNF agents are more efficacious,' lead author Marc Ferrante...Ferrante noted that the economic considerations involved in deciding between a biosimilar and an originator were not part of the research but that 'there will be a difference in costs.'"

Media quote

Therapeutic Drug Monitoring in IMIDs (Autoimmune Learning Network - HMP) - "'With Dr Cheifetz's help, we are working on a study of HS patients. We're using drug levels published for GI and are starting to figure out therapeutic responders...In addition, patients with perianal Crohn disease who were de-escalated to an infliximab level of 3 ug/mL experience reopening of their old fistulae."

Media quote

Infliximab Monotherapy, Combination Therapy Comparable Among Biologic-Naïve Patients With IBD (HCPLive) - "'Whether the advantages of combining an immunosuppressant with intravenous infliximab are also true for combination therapy with subcutaneous infliximab and immunosuppressants has not hitherto been addressed,' wrote Geert D'Haens..."

Media quote

Study Details Perceptions of Biosimilars Among Patients with Immune-Mediated Diseases (HCPLive) - "In the current study, which was funded by Boehringer Ingelheim, a team of investigators led by Allan Gibofsky...With this in mind, investigators conducted an online survey using a 16-item questionnaire sent go individuals within the Dynata consumer panel."

Media quote

Prometheus Launches New Indication for PredictrPK IFX, A Precision-Guided Dosing Test for IBD (PRNewswire) - "Results from a prospective intervention trial published in Inflammatory Bowel Diseases, led by Marla Dubinsky...examined the impact of patient pharmacokinetics (PK) on individualized dosing during IFX induction and outcomes....These findings support the clinical utility of individualized, PK-based, optimization of IFX during induction and the value precision-guided dosing has to significantly improve the efficacy of a first-line biologic.'"

Media quote

Strategies for Cost Reduction in the Management of Moderate-to-Severe Psoriasis (SDDS 2023) - "Phototherapy and oral systemic agents were the most cost limiting options, with biosimilars being the third most cost limiting option....Phototherapy is considered an efficacious, safe and inexpensive first line therapy for moderate-tosevere psoriasis. However, if patients fail to see improvement with only phototherapy, oral systemic agents may be an appropriate adjunctive treatment. Patients may also want to be trialed on infliximabaxxq, a biosimilar with similar efficacy to infliximab, and a considerably lower cost."

Review

Withdrawing Infliximab not Recommended for Crohn’s Disease Treatment (HCPLive) - "A team, led by Edouard Louis...compared the relapse rate and the time spent in remission over 2 years between patients with Crohn's disease treated with the standard combination therapy and patients who stop either the infliximab or immunosuppressant portion of the therapy."

Media quote

Subcutaneous Infliximab And the FODMAP Diet (Gastroendonews) - "Although infliximab is one of the oldest therapies for IBD, first approved by the FDA for the treatment of Crohn's disease in 1998, it remains among the most effective treatments available....I think that patients who can work with a dietitian knowledgeable about IBD should do so. Virtual visits may offer more options for providers to refer patients to a registered dietitian specializing in IBD."

Online posting